Perdonà S - Search Results

1

Long non-coding RNA containing ultraconserved genomic region 8 promotes bladder cancer tumorigenesis.

Olivieri M, Ferro M, Terreri S, Durso M, Romanelli A, Avitabile C, De Cobelli O, Messere A, Bruzzese D, Vannini I, Marinelli L, Novellino E, Zhang W, Incoronato M, Ilardi G, Staibano S, Marra L, Franco R, Perdonà S, Terracciano D, Czerniak B, Liguori GL, Colonna V, Fabbri M, Febbraio F, Calin GA, Cimmino A. Olivieri M, et al. Among authors: perdona s. Oncotarget. 2016 Apr 12;7(15):20636-54. doi: 10.18632/oncotarget.7833. Oncotarget. 2016. PMID: 26943042 Free PMC article.

2

Oncologic outcomes following radical nephroureterectomy for upper tract urothelial carcinoma: a literature review.

Grob G, Rogers D, Pandolfo SD, Vourganti S, Buscarini M, Mehrazin R, Grob BM, Mir MC, Perdonà S, Derweesh IH, Franco A, Cherullo EE, Hemal AK, Autorino R. Grob G, et al. Among authors: perdona s. Transl Androl Urol. 2023 Aug 31;12(8):1351-1362. doi: 10.21037/tau-22-882. Epub 2023 Jul 28. Transl Androl Urol. 2023. PMID: 37680219 Free PMC article. Review.

3

Qualitative Assessment of Contrast-Enhanced Ultrasound in Differentiating Clear Cell Renal Cell Carcinoma and Oncocytoma.

Tufano A, Leonardo C, Di Bella C, Lucarelli G, Dolcetti V, Dipinto P, Proietti F, Flammia RS, Anceschi U, Perdonà S, Franco G, Sciarra A, Di Pierro GB, Cantisani V. Tufano A, et al. Among authors: perdona s. J Clin Med. 2023 Apr 23;12(9):3070. doi: 10.3390/jcm12093070. J Clin Med. 2023. PMID: 37176510 Free PMC article.

4

The Value of Fournier's Gangrene Scoring Systems on Admission to Predict Mortality: A Systematic Review and Meta-Analysis.

Tufano A, Dipinto P, Passaro F, Anceschi U, Franco G, Flammia RS, Proietti F, Antonelli L, Di Pierro GB, Prata F, Rullo R, Perdonà S, Leonardo C. Tufano A, et al. Among authors: perdona s. J Pers Med. 2023 Aug 22;13(9):1283. doi: 10.3390/jpm13091283. J Pers Med. 2023. PMID: 37763051 Free PMC article. Review.

5

[Role of crural inguinal lymphadenectomy and dynamic sentinel lymph node biopsy in lymph node staging in squamous-cell carcinoma of the penis. Our experience].

Perdonà S, Gallo L, Claudio L, Marra L, Gentile M, Gallo A. Perdonà S, et al. Tumori. 2003 Jul-Aug;89(4 Suppl):276-9. Tumori. 2003. PMID: 12903620 Italian.

6

Concomitant CXCR4 and CXCR7 expression predicts poor prognosis in renal cancer.

D'Alterio C, Consales C, Polimeno M, Franco R, Cindolo L, Portella L, Cioffi M, Calemma R, Marra L, Claudio L, Perdonà S, Pignata S, Facchini G, Cartenì G, Longo N, Pucci L, Ottaiano A, Costantini S, Castello G, Scala S. D'Alterio C, et al. Among authors: perdona s. Curr Cancer Drug Targets. 2010 Nov;10(7):772-81. doi: 10.2174/156800910793605839. Curr Cancer Drug Targets. 2010. PMID: 20578990

7

Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients.

Buonerba C, Federico P, D'Aniello C, Rescigno P, Cavaliere C, Puglia L, Ferro M, Altieri V, Perdonà S, De Placido S, Di Lorenzo G. Buonerba C, et al. Among authors: perdona s. Cancer Chemother Pharmacol. 2011 Jun;67(6):1455-61. doi: 10.1007/s00280-011-1594-z. Epub 2011 Mar 2. Cancer Chemother Pharmacol. 2011. PMID: 21365219 Clinical Trial.

8

Combined magnetic resonance spectroscopy and dynamic contrast-enhanced imaging for prostate cancer detection.

Perdonà S, Di Lorenzo G, Autorino R, Buonerba C, De Sio M, Setola SV, Fusco R, Ronza FM, Caraglia M, Ferro M, Petrillo A. Perdonà S, et al. Urol Oncol. 2013 Aug;31(6):761-5. doi: 10.1016/j.urolonc.2011.07.010. Epub 2011 Sep 9. Urol Oncol. 2013. PMID: 21906966

9

Chondroitin sulphate enhances the antitumor activity of gemcitabine and mitomycin-C in bladder cancer cells with different mechanisms.

Ferro M, Giuberti G, Zappavigna S, Perdonà S, Facchini G, Sperlongano P, Porto S, Di Lorenzo G, Buonerba C, Abbruzzese A, Altieri V, Caraglia M. Ferro M, et al. Among authors: perdona s. Oncol Rep. 2012 Feb;27(2):409-15. doi: 10.3892/or.2011.1526. Epub 2011 Oct 31. Oncol Rep. 2012. PMID: 22052369

10

High CXCR4 expression correlates with sunitinib poor response in metastatic renal cancer.

D' Alterio C, Portella L, Ottaiano A, Rizzo M, Carteni G, Pignata S, Facchini G, Perdona S, Di Lorenzo G, Autorino R, Franco R, La Mura A, Nappi O, Castello G, Scala S. D' Alterio C, et al. Among authors: perdona s. Curr Cancer Drug Targets. 2012 Jul;12(6):693-702. doi: 10.2174/156800912801784820. Curr Cancer Drug Targets. 2012. PMID: 22463589

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

164 results

Search Page